Tirzepatide
Tirzepatide is a synthetic dual-agonist peptide designed to interact with GLP-1 and GIP receptor pathways. Through this dual-agonist mechanism, it enables the study of metabolic signaling and peptide-mediated biological processes. Commonly utilized in research settings to explore glucose dynamics and receptor signaling mechanisms. Supplied by Peptico for research-use only.
All Orders Ship within
24 Business Hours
Free Shipment Protection
Priority Shipment Options Available at Checkout
- For maximum potency, lyophilized materials may generally be stored between 2°C and 8°C (36°F to 46°F) for up to 4 weeks when maintained in their original, sealed lyophilized form.
- Maintain a cool and dry environment.
- Protect from moisture and light.
- Minimize exposure to humidity and temperature fluctuations.
- For maximum potency and long-term preservation, lyophilized materials may generally be stored between -20°C and -80°C (-4°F to -112°F) for up to 1 year when preserved in their original, sealed lyophilized form.
- Maintain a cool and dry environment.
- Protect from moisture and light.
- Minimize exposure to humidity and temperature fluctuations.
Important Note:
Storage guidelines apply only to lyophilized material in its original, sealed, and untampered vial.
COA History
All shipped products include a unique batch number printed on the vial label. This batch number corresponds to a third-party Certificate of Analysis tested by an ISO/IEC 17025 accredited laboratory.
The COA attached at the top of this page, along with the COA marked “Current” below, represents the active production batch currently being shipped. This same batch number will appear on the label of your vial.
For previous purchases, please refer to COAs marked “Historical” and match the batch number on your vial to the batch number listed on the corresponding COA.
For a complete record of testing documentation across all products and batches, please visit our COA Vault, which includes both current and historical COAs.
Molecular Profile
What is Tirzepatide?
Scientific compound data sourced from PubChem.
Research
Sources & References
API results related to Tirzepatide.
Tirzepatide compound record
CID: 166567236
20-[[(1S)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-2-methylpropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
Formula: C225H348N48O68 • Molecular weight: 4813
View sourceEnhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study.
Journal of medical economics
Annemans L, Johansson E, Spaepen E et al. • 2026
Publication date: 2026 Dec
View sourceCost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economics
Johansson E, Wilding JPH, Upadhyay N et al. • 2026
Publication date: 2026 Dec
View sourceAnnual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.
Journal of medical economics
Kanumilli N, Osumili B, Evans J et al. • 2026
Publication date: 2026 Dec
View sourceCost-effectiveness and budget-impact analysis of tirzepatide in heart failure with preserved ejection fraction and obesity in the German health-care system.
International journal of cardiology
Estler B, Fröhlich H, Täger T et al. • 2026
Publication date: 2026 Sep 1
View sourceDepressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study.
Journal of affective disorders
Aboukaoud M, Hoch B, Weiser M et al. • 2026
Publication date: 2026 Aug 15
View source⚠️ IMPORTANT RESEARCH NOTICE
This product is NOT for human consumption.
Supplied strictly for laboratory and analytical research use only, it is not intended to diagnose, treat, cure, or prevent any disease, and must not be used for clinical, veterinary, or therapeutic applications.
All information provided, including referenced research and data, is for educational and scientific context only and should NOT be interpreted as medical guidance.
By purchasing, you confirm that you are a qualified individual or entity operating in accordance with applicable local, state, and federal regulations. All responsibility for handling, use, and compliance rests solely with the purchaser.





